REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

@Genesys: Echt eine gute Idee mit den Leerverkäufen hinsichtlich Amis. Hau den mal auf den Sack!👍🏻. Mein Votum hast du mehrfach. Danke!

EMA timeline: Bis Ende des Jahres, FDA bis Januar 2022

Genesys, meinen Seggen hast du. Wird Zeit für nen Arschtritt 😉

Genesys das auf Reddit richtig adressiert, vielleicht auch über Ocgn, könnte eine schöne Aufmerksamkeit generieren. Ausserdem ist Citadel ja auch short auf Redhill, da gibts ja ein richtiges Feindbild

bin im cast und in der telco - bisher keine negativen Überraschungen

Die Frae ist, wie man den ganzen Leerverkäufen am besten begegnet. Ich werde mal einen Bericht zu dem Treiben mit der Aktie in den Foren posten, die sich damals mit der Gamestop-Geschichte befassten. Vielleicht braucht es hier mal einen kräftigen Kinnhaken für die ganzen Leerverkäufer in Amiland. Mal schauen, ob ich da was lostreten kann, nach dem Motto: "Sind die Leerverkäufer potentielle Mörder? - Wie Leerverkäufer die Einführung eines CoVid-Medikaments behindern". Selten lässt sich mit der Gut/Böse-Polarisierung trefflicher spielen. Und die Amis stehen nun mal auf plakative Metaphern. Was haltet ihr von der Idee?

...schon wieder unten der Kurs!

Jemand im webcast? Geht bei mir nicht…

Die amis sind wieder da und drücken den Preis wie jeden Tag.😂

Bin jetzt doch sehr überrascht - solide Darstellung - äußerst positive Aussichten - was auch erfreulich ist, war die Mitteilung der doch sehr kontrollierten Pers.-Kosten - ebenso die steigenden Einnahmen / Erfolge der weiteren Medis außerhalb der Covid-Schiene - und jetzt noch die Zulassung ? die Talsole hätten wir hinter uns 👍

In parallel, we continue to progress our Phase 2/3 study in the U.S. and South Africa with our other novel, once-daily, oral COVID-19 antiviral drug candidate, RHB-107, which has now completed enrollment for Part A of the study, with top-line results expected in the first quarter of 2022. Our Phase 3 study of RHB-204 in pulmonary nontuberculous mycobacteria (NTM) disease continues to enroll patients in the U.S. and progress with Phase 3-stage RHB-104 for Crohn’s disease is expected to speed up thanks to a recent, much-awaited, potential progress in Mycobacterium avium subspecies paratuberculosis (MAP) detection research .” “With a steep reduction in quarterly operating and net loss and continued commercial business growth, leading to a potential commercial operational breakeven before the end of the year, coupled with advanced, exciting and timely R&D pipeline progress, I believe RedHill is well positioned for short, medium and long-term success.”

Mr. Ben-Asher added: “Given the recent emergence of the heavily mutated Omicron variant as well as likely emergence of other variants over time, the importance of drug candidates that act independently of the viral spike protein is growing. This makes both opaganib and RHB-107’s host-targeted mechanism of action, and expected maintenance of effect against new variants, increasingly more relevant in the battle against COVID-19. This quarter saw significant focus on our opaganib Phase 2/3 COVID-19 study. The initial top-line results demanded further investigation and our rigorous post-hoc analysis provided much greater clarity into the potential of novel, orally-administered opaganib in the underserved hospitalized moderately severe patient group. This is a group of patients for which no novel therapeutic pill has shown a benefit until opaganib, which demonstrated a 62% reduction in mortality, improved return to room air and earlier hospital discharge for opaganib-treated patients. The results of this analysis, in a group of more than half the total study population, were consistent with what we had seen in our Phase 2 study and compassionate use experience. Despite being a post-hoc analysis, the consistency across multiple endpoints and territories provides us with a high degree of confidence in the results showing opaganib’s effect in this patient population. This analysis also shed light on key issues of the COVID-19 disease severity classification, suggesting that FiO2 might be an improved method for classifying disease severity and predictor of treatment outcome. We have now provided regulators in various countries with all the necessary data to facilitate discussions on the next steps and we continue to provide the data to regulators in additional countries.”

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “Our U.S. commercial business continues to drive growth, delivering a second consecutive quarterly net revenue record of $21.6 million despite the continuously challenging pandemic environment. Talicia generated another record quarter with 15% growth in new prescriptions, while Movantik continues to perform adding a 1.1% increase to new prescriptions. Both products are also continuing to make strides in gaining both commercial and government formulary coverage. In addition, gross margin increased from 51% in the second quarter to 57% in the third quarter. The Company has successfully attracted a strategic investment from South Korea’s Kukbo and continues to demonstrate responsible financial discipline across the entire business as we strive to achieve our long-term growth aims.”

Sinkt leider schon wieder😢

Die Daten sehen viel besser aus als erwartet. Was die Zeitschiene für EMA angeht, kann RedHill keine Antwort geben, das ist ein laufender Prozess.